{"id":447695,"date":"2021-03-01T17:38:54","date_gmt":"2021-03-01T22:38:54","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=447695"},"modified":"2021-03-01T17:38:54","modified_gmt":"2021-03-01T22:38:54","slug":"hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/","title":{"rendered":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN FRANCISCO, March  01, 2021  (GLOBE NEWSWIRE) &#8212; Hagens Berman urges AstraZeneca PLC <strong>(NASDAQ: AZN) <\/strong>investors to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vnpSUNh4ixnE6ed8FfcgfeSMa2Mw4ae8eY4y44tq6V4a7QUQjI6tan3hLiVYdgqmQgopbkfIM6bRD1QKa8tpkPmEeVn6vly-VPIKitBckB6L0qhhsUWtFNXtXJAklWJq\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">submit their losses now.<\/a>\u00a0A securities fraud class action has been filed and certain investors may have valuable claims.<\/p>\n<p>\n        <strong>Class Period: <\/strong>May 21, 2020 &#8211; Nov. 20, 2020<br \/><strong>Lead Plaintiff Deadline: <\/strong>March 29, 2021<br \/><strong>Visit:<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mAiJmq23BwLHmlxPJRrHMEh4LXzbNkcAlJZgazdpeQBjxCSIej3_-hDYugtNaAwoult0phb8YuU73s-Zz0pXg-rc1cYFp1JMRui0p1Io-GEYcWLCMy3vk9Mf_sLvnsy3BhSsyp1Bd1pm8zN4hCIRyQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.hbsslaw.com\/investor-fraud\/AZN<\/a><br \/><strong>Contact An Attorney Now:<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jz4Er8No4LP--X8mjRqN4EM0xVl-yJPFmgcgN9KW9NGQOml7uXtC8zD9ymvmJQN42hUKVvLF7nn4eDiGN_9TFQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">AZN@hbsslaw.com<\/a><br \/><strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 844-916-0895<\/strong><\/p>\n<p>\n        <strong>AstraZeneca PLC (AZN) Securities Fraud Class Action<\/strong>:<\/p>\n<p>The complaint alleges that Defendants misrepresented and omitted to disclose widespread flaws in the design, execution, and results of the company\u2019s clinical trials of AstraZeneca\u2019s COVID-19 vaccine candidate (AZD1222).<\/p>\n<p>Specifically, Defendants concealed that: (1) a critical manufacturing error resulted in a substantial number of trial participants receiving half the designed dosage; (2) clinical trials consisted of an improper patient makeup that received subtly different treatments undermining any conclusion that could be drawn from the clinical data; (3) certain clinical trial participants had not received a second dose at the designated time points; and (4) the Company failed to include a substantial number of patients over 55 years of age.<\/p>\n<p>Investors allegedly began to learn the truth on Nov. 23, 2020, when AstraZeneca announced an interim analysis of its ongoing trial for AZD1222, which revealed that the company used two different dosing regimens in two trials conducted in the UK and Brazil. In one trial, patents received a half dose followed by a full dose (resulting in 90% efficacy). In the other, patients received two full doses (resulting in 62% efficacy).<\/p>\n<p>Thereafter, investors learned through a series of disclosures that: (1) the differing dosing regimens were due to a known manufacturing error discovered early in the process, (2) the half dose had not been tested in patients over 55, (3) certain trial participants did not timely receive the second dose, and (4) U.S. regulators stated that, absent a clear explanation of discrepancies in the trial results, approval for commercial sale of AZD1222 in the U.S. was unlikely.<\/p>\n<p>In response to this news, the price of AstraZeneca American Depositary Receipts significantly fell.<\/p>\n<p>\u201cWe\u2019re focused on investor losses and proving AstraZeneca knowingly took undisclosed shortcuts in its rush to commercialize AZD1222,\u201d said Reed Kathrein, the Hagens Berman partner leading the investigation.<\/p>\n<p>If you are an AstraZeneca investor, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5lbNdSCZH0yAfd1CBHaaEgTw3A3o7yJOUdhsb-fnbUaIcuo2fCb9vXsIL73zxHYwxzgzkZJMXozPvSKP0bP7IgACwIe6IaXI_JMTTu9XMGFPSKRDMNGr_e2CwwW_DRn9V1dWX1zgr8OwOq93inOof_c8kW6ILvpdff-QntD-ZiM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">click here to discuss your legal rights with Hagens Berman<\/a>.<\/p>\n<p>\n        <strong>Whistleblowers: <\/strong>Persons with non-public information regarding AstraZeneca should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at <strong>844-916-0895<\/strong> or email <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jz4Er8No4LP--X8mjRqN4MjTV4dBtgXN6BRg_AH_4qwNfDAxKU6HA7UXS7IQlYqA1veUDFp28XKSaO1sDEWShg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">AZN@hbsslaw.com<\/a>.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zF6qDsHsB74cRCwmS7qkSQhjJQfrGSy7rDvH5frMZrIX_nFky2qMyzD0nZPfBTqnzGkH0o4zK5ewNud59af25leXl8wvqrgDmCIPA1fcdLQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <u>About Hagens Berman<\/u><br \/>\n        <\/a><br \/>\n        <br \/>Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bXDk4EgJJ4zflYWrCqchaimbESme7ogztX51g2jll_RG7tW6TCJ7jnX0fNK_jmIkgqukgjiFkT9UKDXp3A3x-Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">hbsslaw.com<\/a>. For the latest news visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vBOtYx4QC7KAEN8RRv5Q6rOIhIUw9S4xypZdBwn0jklF9nLzoDhpC7a3_4t6vWogQlIzjxKRH3KKZgno-f5NvbrwAUYhQfQVeMaWSRSF6vM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>newsroom<\/u><\/a> or follow us on Twitter at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MejKlLPc4gQq251OTetW8YtKBEe61F5oJ4fscp6mm38nOJYSs_VLjMFbB6gdJ0D4zHeh3iYY9L8fohwV2yKCAwtYw2WR_VAETAUPrrdoFho=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>@classactionlaw<\/u><\/a>.<\/p>\n<p>\n        <u>Contact: <\/u><br \/>\n        <br \/>Reed Kathrein, 844-916-0895<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/d446704a-fe3a-494e-b5da-666122023aa0\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) &#8212; Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now.\u00a0A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: May 21, 2020 &#8211; Nov. 20, 2020Lead Plaintiff Deadline: March 29, 2021Visit:www.hbsslaw.com\/investor-fraud\/AZNContact An Attorney Now:AZN@hbsslaw.com\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 844-916-0895 AstraZeneca PLC (AZN) Securities Fraud Class Action: The complaint alleges that Defendants misrepresented and omitted to disclose widespread flaws in the design, execution, and results of the company\u2019s clinical trials of AstraZeneca\u2019s COVID-19 vaccine candidate (AZD1222). Specifically, Defendants concealed that: (1) a critical manufacturing error resulted in a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-447695","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) &#8212; Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now.\u00a0A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: May 21, 2020 &#8211; Nov. 20, 2020Lead Plaintiff Deadline: March 29, 2021Visit:www.hbsslaw.com\/investor-fraud\/AZNContact An Attorney Now:AZN@hbsslaw.com\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 844-916-0895 AstraZeneca PLC (AZN) Securities Fraud Class Action: The complaint alleges that Defendants misrepresented and omitted to disclose widespread flaws in the design, execution, and results of the company\u2019s clinical trials of AstraZeneca\u2019s COVID-19 vaccine candidate (AZD1222). Specifically, Defendants concealed that: (1) a critical manufacturing error resulted in a &hellip; Continue reading &quot;HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-01T22:38:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm\",\"datePublished\":\"2021-03-01T22:38:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/\"},\"wordCount\":520,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/\",\"name\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI=\",\"datePublished\":\"2021-03-01T22:38:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/","og_locale":"en_US","og_type":"article","og_title":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm - Market Newsdesk","og_description":"SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) &#8212; Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now.\u00a0A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: May 21, 2020 &#8211; Nov. 20, 2020Lead Plaintiff Deadline: March 29, 2021Visit:www.hbsslaw.com\/investor-fraud\/AZNContact An Attorney Now:AZN@hbsslaw.com\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0 844-916-0895 AstraZeneca PLC (AZN) Securities Fraud Class Action: The complaint alleges that Defendants misrepresented and omitted to disclose widespread flaws in the design, execution, and results of the company\u2019s clinical trials of AstraZeneca\u2019s COVID-19 vaccine candidate (AZD1222). Specifically, Defendants concealed that: (1) a critical manufacturing error resulted in a &hellip; Continue reading \"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-01T22:38:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm","datePublished":"2021-03-01T22:38:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/"},"wordCount":520,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/","name":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI=","datePublished":"2021-03-01T22:38:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MjI1NCM0MDQyNjkxIzIwMTg1MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hagens-berman-national-trial-attorneys-reminds-astrazeneca-azn-investors-of-pending-securities-class-action-encourages-investors-who-suffered-losses-to-contact-the-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/447695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=447695"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/447695\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=447695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=447695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=447695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}